| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:iCRT5
CAS:18623-44-4
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
|
| | 4-[5-(3,4-DIMETHOXY-BENZYLIDENE)-4-OXO-2-THIOXO-THIAZOLIDIN-3-YL]-BUTYRIC ACID Basic information |
| | 4-[5-(3,4-DIMETHOXY-BENZYLIDENE)-4-OXO-2-THIOXO-THIAZOLIDIN-3-YL]-BUTYRIC ACID Chemical Properties |
| Boiling point | 571.2±60.0 °C(Predicted) | | density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to 30 mg/ml) | | form | solid | | pka | 4.59±0.10(Predicted) | | color | Yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| | 4-[5-(3,4-DIMETHOXY-BENZYLIDENE)-4-OXO-2-THIOXO-THIAZOLIDIN-3-YL]-BUTYRIC ACID Usage And Synthesis |
| Description | iCRT5 (18623-44-4) is a selective CRT (β-catenin-responsive transcription) inhibitor.1? IC50=18 nM for Wnt responsive STF16 luciferase. Acts via interfering with the β-catenin, TCF4 interaction.1?Displays poor inhibition of cell proliferation in triple-negative breast cancer cells.2?Increases the surface expression of MHCII, CD80 and CD86 on unstimulated dendritic cells (DCs) with no detrimental effects on immune-phenotype of stimulated DCs.3?Modulators of Wnt signaling show great promise in animal models of several cancers.4?Cell permeable. | | Uses | iCRT5 is a selective CRT (β-catenin-responsive transcription) inhibitor. | | References | 1) Gonsalves?et al.?(2011),?An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway; Proc. Natl. Acad. Sci. USA,?108?5954
2) Bilir?et al. (2013),?Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells; J. Transl. Med.,?11?280
3) Kafer?et al.?(2016),?Inhibitors of β-catenin affect the immune-phenotype and functions of dendritic cells in an inhibitor-specific manner; Immunopharmacol.,?32?118
4) Anastas?et al. (2013),?WNT signaling pathways as therapeutic targets in cancer; Nat. Rev. Cancer,?13?11 |
| | 4-[5-(3,4-DIMETHOXY-BENZYLIDENE)-4-OXO-2-THIOXO-THIAZOLIDIN-3-YL]-BUTYRIC ACID Preparation Products And Raw materials |
|